Saglik Bilimleri Universitesi Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Istanbul Turkey (1903)

Organization Overview

First Clinical Trial
2004
NCT00271427
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Ayşe Toraman | Dep. of Nuc. Med., Gulhane Military Academy of Medicine | GATA Ankara | Gulhane Military Academy of Medicine | Gülhane Military Medical Academy | Gulhane Military Medical Academy, Department of Gastroenterology | GulhaneResearch and Training Hospital | Gulhane School of Medicine | Gulhane School of Medicine, Department of Endocrinology and Metabolism | Gulhane Training and Research Hospital | Istanbul Saglik Bilimleri University | Istanbul Sağlık Bilimleri University | Murat Kantarcioglu | Saglik Bilimleri Universitesi | Sağlık Bilimleri Üniversitesi Bursa Yüksek İhtisas Eğitim Ve Araştırma Hastanesi | Sağlık Bilimleri Üniversitesi Fatih Sultan Mehmet Eğitim Ve Araştırma Hastanesi | Saglik Bilimleri Universitesi Gulhane Tip Fakultesi | Sağlık Bilimleri Üniversitesi Kayseri Şehir hastanesi | Saglik Bilimleri University | Sağlık Bilimleri University | Yasemin Çırak

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brucellosis (Phase 4)

Colitis, Ulcerative (Phase 3)

Communicable Diseases (Phase 2)

Constipation (Phase 3)

Crohn Disease (Phase 3)

Diabetic Nephropathies (Phase 4)

Diarrhea (Phase 2)

Dysentery (Phase 2)

Familial Mediterranean Fever (Phase 4)

Fecal Impaction (Phase 3)

Fever (Phase 4)

Fibrosis (Phase 2)

Hepatitis (Phase 2)

Hereditary Autoinflammatory Diseases (Phase 4)

Hypertension (Phase 4)

Hypoglycemia (Phase 4)

Hypogonadism (Phase 4)

Infections (Phase 2)

Inflammation (Phase 4)

Inflammatory Bowel Diseases (Phase 3)

Insulin Resistance (Phase 4)

Kidney Diseases (Phase 4)

Liver Cirrhosis (Phase 2)

Metabolic Syndrome (Phase 4)

Obesity (Phase 4)

Pilonidal Sinus (Phase 4)

Proteinuria (Phase 4)

Renal Insufficiency, Chronic (Phase 4)

Vascular Diseases (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 64
  • # of Trial APIs: 27